Sandoz Reports Real World Study Results of GP2013 (biosimilar, rituximab) for the Treatment of Rheumatoid Arthritis
Shots:
- The study incl. 2 yr. of RWE evaluating rituximab biosimilar GP2013 vs biologic originator RTX showed that the patients who switched from rituximab to GP2013 experienced positive results & maintained clinical outcomes
- Satisfactory treatment responses in rituximab-naïve patients & those who underwent a mandatory switch in Norway, drug retention rates in switched vs naïve group @1yr. (84% vs 64%) & 2yr. (60% vs 49%) with no deterioration in disease activity outcomes
- Disease duration (14 vs 3yrs.), 91% of rituximab-naïve patients received 2000mg GP2013 in 1st cycle; 85% of switched patients received 1000 or 500mg. In the rituximab-naïve group, improvements in most disease activity measure incl. PROs during the 1yr. of treatment and maintained at 2yrs.
Ref: Center For Biosimilars | Image: Sandoz
Related News:- Sandoz Reports the EMA Acceptance of MAA for Proposed Biosimilar Denosumab
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
